image: Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine, and Alex Aliper, PhD, Co-Founder and President of Insilico Medicine sharing insights at multiple panel discussions during the upcoming Abu Dhabi Global Health Week.
Credit: Insilico Medicine
Bringing together 15,000 attendees including healthcare leaders, policymakers, innovators, and disruptors from 90 countries, Abu Dhabi Global Health Week 2025 will be taking place at the Abu Dhabi National Exhibition Centre (ADNEC) from April 15-17, aiming for a global, sustainable and resilient healthcare network.
As a pioneer in generative AI-driven healthcare, Insilico Medicine highly values cutting-edge communication at global conferences, with Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine, and Alex Aliper, PhD, Co-Founder and President of Insilico Medicine sharing insights at multiple panel discussions during the upcoming Abu Dhabi Global Health Week. Besides, Insilico is actively seeking collaboration opportunities, and in-person meetings are also welcomed at Booth #5A14.
Alex Zhavoronkov, PhD will explore the intersection of artificial intelligence, healthcare innovation, and global investment in longevity in a series of panel discussions, including a session titled “Unlocking AI’s Potential in Healthcare: A Governance Framework for Enabling Innovation” starting 11:00 AM, April 16; and two sessions titled “Top Targets for AI-enabled Drug Discovery” and “UAE as a Global Longevity Investment Hub: Opportunities and Challenges”, starting 9:30 AM and 10:40 AM on April 17, respectively.
On April 16, Alex Aliper, PhD will be sharing about end-to-end AI application in drug discovery process in a session titled “Big Data Integration: Bridging the Gap Between Research and Clinical Practice” at 2:30-3:30 PM.
In 2025, Abu Dhabi Global Health Week focuses on longevity and precision health, health system resilience and sustainability, digital health and AI, and investment in life sciences, hoping to pave the way towards longevity, redefining health and well-being.
About Insilico Medicine
Insilico Medicine, a globally pioneering tech-bio company powered by generative AI, utilizes its proprietary Pharma.AI platform and cutting-stage automated laboratory to accelerate drug discovery and advance innovations in life sciences research. By integrating the technologies of AI and automation, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Ten molecules in Insilico's AI-driven pipeline portfolio have received IND clearance, with the most advanced being Rentosertib (formerly ISM001-055), a potentially first-in-class drug candidate for idiopathic pulmonary fibrosis, which has completed Phase 2a clinical studies with encouraging results. Additionally, Insilico is exploring exciting new frontiers empowered by AI and automated capabilities, including breakthroughs in aging research, sustainable chemistry, and agricultural innovation.
For more information, please visit www.insilico.com.